within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AF01_Isocarboxazid;
model Isocarboxazid 
   extends Pharmacolibrary.Drugs.ATC.N.N06AF01;

  annotation(Documentation(
    info ="<html><body><p>Isocarboxazid is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) formerly used as an antidepressant for the treatment of major depressive disorder. Due to safety concerns, especially dietary restrictions and risk of hypertensive crisis, its clinical use has been largely discontinued in many countries.</p><h4>Pharmacokinetics</h4><p>No specific published human pharmacokinetic parameter studies were identified for isocarboxazid; estimates are provided based on general MAOI and pharmacokinetic principles, assuming healthy adult oral administration.</p><h4>References</h4><ol><li><p>Conley, BA, et al., &amp; Grieshaber, CK (1991). The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide. <i>Cancer chemotherapy and pharmacology</i> 28(1) 33–38. DOI:<a href=&quot;https://doi.org/10.1007/BF00684953&quot;>10.1007/BF00684953</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2040031/&quot;>https://pubmed.ncbi.nlm.nih.gov/2040031</a></p></li><li><p>Clemmesen, L, et al., &amp; Rafaelsen, OJ (1984). Assessment of the anticholinergic effects of antidepressants in a single-dose cross-over study of salivation and plasma levels. <i>Psychopharmacology</i> 82(4) 348–354. DOI:<a href=&quot;https://doi.org/10.1007/BF00427684&quot;>10.1007/BF00427684</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6427827/&quot;>https://pubmed.ncbi.nlm.nih.gov/6427827</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Isocarboxazid;
